Biology of Blood and Marrow Transplantation
Volume 10, Issue 3 , Pages 178-185 , March 2004

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation

  • Daniel R Couriel

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • Corresponding Author Information Correspondence and reprint requests: Daniel R. Couriel, MD, Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095 USA
    • ,
  • Rima M Saliba

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Sergio Giralt

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Issa Khouri

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Borje Andersson

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Marcos de Lima

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Chitra Hosing

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Paolo Anderlini

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Michelle Donato

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Karen Cleary

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • James Gajewski

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Joyce Neumann

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Cindy Ippoliti

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Gabriela Rondon

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Agueda Cohen

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Richard Champlin

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

Received 2 July 2003 ,Accepted 23 October 2003.

References 

  1. Martin PJ, Schoch G, Fisher L, et al.  A retrospective analysis of therapy for acute graft-versus-host disease (initial treatment). Blood. 1990;76:1464–1472
  2. Martin PJ, Schoch G, Fisher L, et al.  A retrospective analysis of therapy for acute graft-versus-host disease (secondary treatment). Blood. 1991;77:1821–1828
  3. Vogelsang GB, Wagner JE. Graft-versus-host disease. Hematol Oncol Clin North Am. 1990;4:625–639
  4. Giralt S, Estey E, Albitar M, et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy (harnessing graft-versus-leukemia without myeloablative therapy). Blood. 1997;89:4531–4536
  5. Giralt S, Thall PF, Khouri I, et al.  Melphalan and purine analog-containing preparative regimens (reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation). Blood. 2001;97:631–637
  6. Khouri IF, Saliba RM, Giralt SA, et al.  Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma (low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality). Blood. 2001;98:3595–3599
  7. McSweeney PA, Niederwieser D, Shizuru JA, et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies (replacing high-dose cytotoxic therapy with graft-versus-tumor effects). Blood. 2001;97:3390–3400
  8. Champlin R, Khouri I, Shimoni A, et al.  Harnessing graft-versus-malignancy (non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy). Br J Haematol. 2000;111:18–29
  9. Hill GR, Crawford JM, Cooke KR, et al.  Total body irradiation and acute graft-versus-host disease (the role of gastrointestinal damage and inflammatory cytokines). Blood. 1997;90:3204–3213
  10. Couriel DR, Hicks K, Giralt S, et al.  Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol. 2000;12:582–587
  11. Fegan C, Poynton CH, Whittaker JA. The gut mucosal barrier in bone marrow transplantation. Bone Marrow Transplant. 1990;5:373–377
  12. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease (rationale for the use of cytokine shields in allogeneic bone marrow transplantation). Blood. 2000;95:2754–2759
  13. Ferrara JL. The cytokine modulation of acute graft-versus-host disease. Bone Marrow Transplant. 1998;21(suppl 3):S13–S15
  14. Przepiorka D, Khouri I, Ippoliti C, et al.  Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999;24:763–768
  15. Przepiorka D, Weisdorf D, Martin P, et al.  1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–828
  16. Yam PY, Petz LD, Knowlton RG, et al.  Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation. 1987;43:399–407
  17. Prentice RL, Kalbfleisch JD, Peterson AV, et al.  The analysis of failure times in the presence of competing risks. Biometrics. 1978;34:541–554
  18. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14:1707–1723
  19. Michallet M, Bilger K, Garban F, et al.  Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens (impact of pretransplantation and posttransplantation factors on outcome). J Clin Oncol. 2001;19:3340–3349
  20. Mattsson J, Uzunel M, Brune M, et al.  Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol. 2001;115:935–944

PII: S1083-8791(03)00419-1

doi: 10.1016/j.bbmt.2003.10.006

Biology of Blood and Marrow Transplantation
Volume 10, Issue 3 , Pages 178-185 , March 2004

Article Tools

* Image Usage & Resolution